Pages that link to "Q35558208"

The following pages link to Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. (Q35558208):

Displaying 49 items.

• Acute and subacute idiopathic interstitial pneumonias (Q26824327) (← links)
• PAMPs and DAMPs as triggers for DIC (Q27013790) (← links)
• Successful treatments with polymyxin B hemoperfusion and recombinant human thrombomodulin for fulminant Clostridium difficile-associated colitis with septic shock and disseminated intravascular coagulation: a case report (Q28828482) (← links)
• Post-marketing surveillance data of thrombomodulin alfa: sub-analysis in patients with sepsis-induced disseminated intravascular coagulation (Q30880390) (← links)
• The efficacy of recombinant human soluble thrombomodulin for the treatment of shiga toxin-associated hemolytic uremic syndrome model mice (Q33420531) (← links)
• Carbon monoxide-releasing molecule-2 suppresses thrombomodulin and endothelial protein C receptor expression of human umbilical vein endothelial cells induced by lipopolysaccharide in vitro (Q33760597) (← links)
• Combination therapy with sivelestat and recombinant human soluble thrombomodulin for ARDS and DIC patients. (Q34155686) (← links)
• Thrombomodulin in the management of acute cholangitis-induced disseminated intravascular coagulation (Q34932581) (← links)
• The Japanese guidelines for the management of sepsis (Q35107094) (← links)
• Assessment of Fibrinolysis in Sepsis Patients with Urokinase Modified Thromboelastography. (Q35755770) (← links)
• The efficacy of recombinant human soluble thrombomodulin for obstetric disseminated intravascular coagulation: a retrospective study (Q36198065) (← links)
• Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis (Q36715005) (← links)
• Aging exacerbates microvascular endothelial damage induced by circulating factors present in the serum of septic patients. (Q36863020) (← links)
• Efficacy of recombinant thrombomodulin for DIC after deceased donor liver transplantation: a case report (Q37156086) (← links)
• Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial (Q37576659) (← links)
• Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding (Q37655890) (← links)
• Immunomodulatory therapy for sepsis: an update (Q37949639) (← links)
• Efficacy of recombinant human soluble thrombomodulin in severe postpartum hemorrhage with disseminated intravascular coagulation. (Q38001988) (← links)
• The immune response: targets for the treatment of severe sepsis (Q38068423) (← links)
• The coagulation system in melioidosis: from pathogenesis to new treatment strategies (Q38222979) (← links)
• Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines (Q38292751) (← links)
• Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials (Q38670135) (← links)
• Septic shock due to Aeromonas hydrophila bacteremia in a patient with alcoholic liver cirrhosis: a case report (Q40179773) (← links)
• Septic shock caused by Klebsiella oxytoca: An autopsy case and a survival case with driving Extracorporeal Membrane Oxygenation (Q40222848) (← links)
• Population pharmacokinetics of thrombomodulin alfa in pediatric patients with hematological malignancy and disseminated intravascular coagulation (Q40544137) (← links)
• Recombinant human soluble thrombomodulin administration improves sepsis-induced disseminated intravascular coagulation and mortality: a retrospective cohort study (Q41034752) (← links)
• Recent Change in Treatment of Disseminated Intravascular Coagulation in Japan: An Epidemiological Study Based on a National Administrative Database (Q41307276) (← links)
• Observational study to compare antithrombin and thrombomodulin for disseminated intravascular coagulation (Q41595614) (← links)
• Recombinant human soluble thrombomodulin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study (Q41664315) (← links)
• Evaluation of the effect of recombinant thrombomodulin on a lipopolysaccharide-induced murine sepsis model (Q41929862) (← links)
• Quantitative analysis of thrombomodulin-mediated conversion of protein C to APC: translation from in vitro to in vivo. (Q42040549) (← links)
• Thrombomodulin: a bifunctional modulator of inflammation and coagulation in sepsis (Q42589170) (← links)
• A Report of Disseminated Carcinomatosis of the Bone Marrow Originating from Transverse Colon Cancer Successfully Treated with Chemotherapy Using XELOX plus Bevacizumab (Q42787227) (← links)
• Use of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation after intestinal perforation (Q43163829) (← links)
• Low ADAMTS-13 activity during hemorrhagic events with disseminated intravascular coagulation (Q43839468) (← links)
• Management of disseminated intravascular coagulation: current insights on antithrombin and thrombomodulin treatments (Q48516198) (← links)
• Potential effect of recombinant thrombomodulin on ischemia-reperfusion liver injury in rats (Q49719996) (← links)
• Pharmacokinetics of recombinant human soluble thrombomodulin in disseminated intravascular coagulation patients with acute renal dysfunction (Q50224294) (← links)
• Recombinant Human Soluble Thrombomodulin Contributes to Reduced Mortality in Sepsis Patients with Severe Respiratory Failure: A Retrospective Observational Study Using a Multicenter Dataset (Q51732708) (← links)
• Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. (Q53116575) (← links)
• Efficacy of recombinant human soluble thrombomodulin for childhood hemolytic uremic syndrome. (Q54302067) (← links)
• Disseminated intravascular coagulation (Q56172333) (← links)
• Recombinant human soluble thrombomodulin improves mortality in patients with sepsis especially for severe coagulopathy: a retrospective study (Q56518823) (← links)
• Circulating activated protein C levels are not increased in septic patients treated with recombinant human soluble thrombomodulin (Q57067780) (← links)
• Successful treatment of disseminated intravascular coagulation by recombinant human soluble thrombomodulin in patients with acute myeloid leukemia (Q58083422) (← links)
• Current concepts in the management of disseminated intravascular coagulation (Q84340569) (← links)
• Persistent hypocoagulability in patients with septic shock predicts greater hospital mortality: impact of impaired thrombin generation (Q84464759) (← links)
• Concomitant Versus Individual Administration of Antithrombin and Thrombomodulin for Sepsis-Induced Disseminated Intravascular Coagulation: A Nationwide Japanese Registry Study (Q87852714) (← links)
• Recombinant human thrombomodulin attenuated sepsis severity in a non-surgical preterm mouse model (Q92669248) (← links)